Literature DB >> 17670842

The UDP-glucuronosyltransferase 2B7 isozyme is responsible for gemfibrozil glucuronidation in the human liver.

Yuji Mano1, Takashi Usui, Hidetaka Kamimura.   

Abstract

Gemfibrozil, a fibrate hypolipidemic agent, is eliminated in humans by glucuronidation. A gemfibrozil glucuronide has been reported to show time-dependent inhibition of cytochrome P450 2C8. Comprehensive assessment of the drug interaction between gemfibrozil and cytochrome P450 2C8 substrates requires a clear understanding of gemfibrozil glucuronidation. However, the primary UDP-glucuronosyltransferase (UGT) isozymes responsible for gemfibrozil glucuronidation remain to be determined. Here, we identified the main UGT isozymes involved in gemfibrozil glucuronidation. Evaluation of 12 recombinant human UGT isozymes shows gemfibrozil glucuronidation activity in UGT1A1, UGT1A3, UGT1A9, UGT2B4, UGT2B7, and UGT2B17, with UGT2B7 showing the highest activity. The kinetics of gemfibrozil glucuronidation in pooled human liver microsomes (HLMs) follows Michaelis-Menten kinetics with high and low affinity components. The high affinity K(m) value was 2.5 microM, which is similar to the K(m) value of gemfibrozil glucuronidation in recombinant UGT2B7 (2.2 microM). In 16 HLMs, a significant correlation was observed between gemfibrozil glucuronidation and both morphine 3-OH glucuronidation (r = 0.966, p < 0.0001) and flurbiprofen glucuronidation (r = 0.937, p < 0.0001), two reactions mainly catalyzed by UGT2B7, whereas no significant correlation was observed between gemfibrozil glucuronidation and either estradiol 3beta-glucuronidation and propofol glucuronidation, two reactions catalyzed by UGT1A1 and UGT1A9, respectively. Flurbiprofen and mefenamic acid inhibited gemfibrozil glucuronidation in HLMs with similar IC(50) values to those reported in recombinant UGT2B7. These results suggest that UGT2B7 is the main isozyme responsible for gemfibrozil glucuronidation in humans.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17670842     DOI: 10.1124/dmd.107.017269

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  9 in total

1.  Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone.

Authors:  Christina L Aquilante; Lisa A Kosmiski; David W A Bourne; Lane R Bushman; Elizabeth B Daily; Kyle P Hammond; Charles W Hopley; Rajendra S Kadam; Alexander T Kanack; Uday B Kompella; Merry Le; Julie A Predhomme; Joseph E Rower; Maha S Sidhom
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

2.  Relative importance of intestinal and hepatic glucuronidation-impact on the prediction of drug clearance.

Authors:  Helen E Cubitt; J Brian Houston; Aleksandra Galetin
Journal:  Pharm Res       Date:  2009-01-31       Impact factor: 4.200

3.  Identification of Uridine 5'-Diphosphate-Glucuronosyltransferases Responsible for the Glucuronidation of Mirabegron, a Potent and Selective β3-Adrenoceptor Agonist, in Human Liver Microsomes.

Authors:  Kentaro Konishi; Daisuke Tenmizu; Shin Takusagawa
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-06       Impact factor: 2.441

Review 4.  Myopathy with statin-fibrate combination therapy: clinical considerations.

Authors:  Terry A Jacobson
Journal:  Nat Rev Endocrinol       Date:  2009-07-28       Impact factor: 43.330

5.  Gemfibrozil concentrations are significantly decreased in the presence of lopinavir-ritonavir.

Authors:  Kristin H Busse; Colleen Hadigan; Cheryl Chairez; Raul M Alfaro; Elizabeth Formentini; Joseph A Kovacs; Scott R Penzak
Journal:  J Acquir Immune Defic Syndr       Date:  2009-10-01       Impact factor: 3.731

6.  Humanized UGT2 and CYP3A transchromosomic rats for improved prediction of human drug metabolism.

Authors:  Yasuhiro Kazuki; Kaoru Kobayashi; Masumi Hirabayashi; Satoshi Abe; Naoyo Kajitani; Kanako Kazuki; Shoko Takehara; Masato Takiguchi; Daisuke Satoh; Jiro Kuze; Tetsushi Sakuma; Takehito Kaneko; Tomoji Mashimo; Minori Osamura; Mari Hashimoto; Riko Wakatsuki; Rika Hirashima; Ryoichi Fujiwara; Tsuneo Deguchi; Atsushi Kurihara; Yasuko Tsukazaki; Naoto Senda; Takashi Yamamoto; Nico Scheer; Mitsuo Oshimura
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-04       Impact factor: 11.205

7.  Enhanced antihyperlipidemic potential of gemfibrozil under co-administration with piperine.

Authors:  S Mohanalakshmi; Shvetank Bhatt; C K Ashok Kumar
Journal:  Curr Res Pharmacol Drug Discov       Date:  2021-03-21

Review 8.  Inhibition of CYP2C8 by Acyl Glucuronides of Gemfibrozil and Clopidogrel: Pharmacological Significance, Progress and Challenges.

Authors:  Manish B Shah
Journal:  Biomolecules       Date:  2022-09-01

9.  2D QSAR Study for Gemfibrozil Glucuronide as the Mechanism-based Inhibitor of CYP2C8.

Authors:  N Taxak; P V Bharatam
Journal:  Indian J Pharm Sci       Date:  2013-11       Impact factor: 0.975

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.